Tagged Articles

chantix-legal.com 44 articles

Chantix is a prescription medication used to treat smoking addiction. Chantix was approved in May of 2006 in the U.S. as an aid to smoking cessation. It has been prescribed to more than 4 million patients in the United States since its approval. Chantix is the first non-nicotine prescription treatment for smoking cessation in almost a decade.

Chantix, is a selective nicotinic acetylcholine receptor partial agonist. As a partial agonist, it both reduces cravings for and decreases the pleasurable effects of cigarettes and other tobacco products, and through these mechanisms, it can assist some patients in stopping smoking.

FDA expands Chantix warnings to include increased heart risks

The black-box warning on Pfizer’s smoking-cessation drug Chantix (varenicline) just got bigger, following the results of a new study that found the drug caused an increased risk of heart attack and other adverse cardiac events in some patients. According to the U.S. Food and Drug Administration, the warning on Chantix labeling will include information about the safety and effectiveness of the drug in patients with existing cardiovascular disease and those with chronic obstructive pulmonary disease (COPD). The FDA issued a new Chantix warning in June, alerting health care professionals and patients to the results of a new randomized, double-blind clinical ... Read More

Chantix significantly increases cardiovascular risks, according to another new study

Last month, the Food and Drug Administration warned of newly discovered cardiovascular risks associated with Pfizer’s popular smoking-cessation drug Chantix. But it turns out those risks, which include higher occurrence of heart attack and other adverse cardiovascular events in Chantix users with heart disease, pale in comparison to the findings of a larger study that found many of the same risks exist in Chantix patients with no heart disease. The new study, published in the Canadian Medical Association Journal, included the results of 14 random, blinded clinical trials that monitored cardiovascular health in more than 8,000 patients taking either Chantix ... Read More

FDA warns of new heart risks associated with Chantix

For many smokers trying to kick their addiction, the latest news about the dangers of Pfizer’s smoking-cessation drug Chantix presents as a damned if you do, damned if you don’t dilemma. The U.S. Food and Drug Administration issued an alert yesterday, warning that use of the popular drug could lead to increased risk of heart attack and other adverse cardiovascular events. The FDA said that a randomized, double-blind, placebo-controlled clinical trial of 700 smokers were given Chantix or a placebo. All of the participating smokers had been previously diagnosed with heart disease. Although results found the risks to be relatively ... Read More

Chantix suicides and violence much more common, newly found reports show

A senior scientist working for the non-profit Institute for Safe Medicine Practices has discovered that Chantix is a much more dangerous drug than has been officially acknowledged after finding hundreds of serious adverse reactions were reported to the FDA by manufacturer Pfizer Inc. through improper channels. When Thomas J. Moore analyzed data collected from the FDA’s Adverse Events Reporting System (AERS), he found nearly 600 reports of serious adverse reactions, including 150 suicides, were mixed in with 26,000 records of non-serious side effects such as nausea and skin irritations. These “missing” reports, some of which go back to 2006, also ... Read More

Support group says Chantix ads conceal important information

WhyQuit, an organization that advocates quitting smoking using the cold turkey method, recently published an article that takes Pfizer to task over its latest Chantix ads. The group claims that the pharmaceutical company’s new television commercials hide information from the viewer – information that, if known, would likely dissuade most smokers from using the drug as a smoking cessation aid. WhyQuit reports that in surveys and scientific studies, more people were found to have successfully quit smoking long term using the cold turkey method than nicotine replacement therapies (NRT). NRT delivers smokeless nicotine to the user through chewing gum, lozenges, ... Read More

Reynolds closer to buying smoking cessation products company

Reynolds American, the second largest American producer of cigarettes and other tobacco products, is in the advanced stages of negotiating a purchase of Niconovum, a Swedish company that manufactures smoking cessation products. If the deal works, as it appears it will, it shows the determination of the tobacco giants to cash in on the “whole cycle of a smoker from the first puff to the last piece of gum,” said Chip Brian, a business analyst for SmarTrend. Based in Helsingborg, Sweden, Niconovum produces nicotine-replacement therapies (NRTS), smoking cessation products designed to provide users with a smokeless form of nicotine relief. ... Read More

“very low nicotine” cigarettes may become sound alternative to Chantix

It’s difficult for some coffee drinkers to imagine life before decaf. Pretty soon it may be difficult for some smokers to imagine life before de-nic. A New York company called 22nd Century Limited recently announced that it is making progress in its development of a very low nicotine (VLN) cigarette that uses a specially engineered and proprietary form of tobacco. Regular “light” cigarette brands contain 20 times the amount of nicotine as VLN cigarettes, a release by the manufacturer states. Even low nicotine cigarettes contain about 8 times more nicotine than a VLN cigarette. Studies have shown that “Differences in ... Read More

FDA favors Chantix over Vaping. Why?

Chantix made an appearance in last week’s issue of the Journal of the American Medical Association (JAMA) when one contributor wrote that the Food and Drug Administration (FDA) has acknowledged receiving nearly 100 reports of suicide and nearly 200 reports of attempted suicide likely linked to the use of Chantix. Additionally, the FDA also said it is compiling reports of Chantix patients being involved in traffic accidents. The JAMA article prompted doctor and authority on smoking, Michael Siegel, to question why the FDA allows Chantix to remain on the market, especially in light of the agency’s threats to remove all vaping ... Read More

Family of musician killed in Chantix rage sues Pfizer

The family of musician Carter Albrecht has filed a lawsuit in a Dallas federal court against Chantix manufacturer Pfizer Inc. Ken and Judy Albrecht allege that the drug manufacturer is responsible for the musician’s death in 2007 because it marketed Chantix, which Carter had been taking at the time of his death, while knowing it to be unsafe. Carter, who played keyboard and guitar for Edie Brickell & The New Bohemians, was shot and killed by his girlfriend’s neighbor in the predawn hours of September 3, 2007. According to Ryann Rathbone, Albrecht’s girlfriend at the time, the two had spent ... Read More

FDA approves stronger, expanded warnings on Chantix labeling

The Food and Drug Administration has approved the new labeling for Chantix packaging. In July, we reported that the agency said it would require stronger warnings on all Chantix labeling, as well as packaging for other smoking cessation drugs Wellbutrin and Zyban (bupropion hydrochloride). All of the drugs have been linked to serious behavioral changes and other symptoms. The new boxed warning on Chantix labeling will read: “Serious neuropsychiatric events, including, but not limited to depression, suicidal ideation, suicide attempt and completed suicide have been reported in patients taking Chantix.” Revised warnings state that neuropsychiatric symptoms and suicidality have been found ... Read More